Paper

NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis

Published Jan 6, 2020 · N. Braidy, Yue Liu

Experimental Gerontology

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Systematic Review

Study Snapshot

Raising NAD+ levels shows promise for age-related degenerative diseases and extending lifespan in small animal models, but long-term human clinical trials are needed to confirm these benefits.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis

References

Citations